USFDAApr 27, 2026, 08:25 AM
ONCY Aligns with FDA for Pivotal Study in Anal Canal Carcinoma
AI Summary
Oncolytics Biotech, Inc. announced it has achieved alignment with the U.S. Food and Drug Administration on plans for a controlled randomized pivotal study. This study will focus on squamous cell carcinoma of the anal canal, marking a significant step forward in the company's clinical development program.
Key Highlights
- Achieved U.S. Food and Drug Administration (FDA) alignment for pivotal study plans.
- Pivotal study to target squamous cell carcinoma of the anal canal.
- Study design will be controlled and randomized.
Price Impact
More from ONCY